The launch of a number of drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome (ACS) treatment market to more than triple in value by 2023, according to research and consulting firm GlobalData.
The ACS treatment market is due to rise from $12.3 billion in 2013 to $43.4 billion within the next decade.
The company’s latest report* states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape.
Amgen’s evolocumab, Sanofi and Regeneron’s alirocumab, and Pfizer’s bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials. According to GlobalData, it is anticipated that these treatments will be launched in the middle of the forecast period.
Dr Eric J. Dimise, GlobalData’s Analyst covering Cardiovascular and Metabolic Disorders, said: “These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment.
“The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion.”
GlobalData has also identified two new anticoagulants, Janssen’s Xarelto and Merck’s Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years.
Dr Dimise concluded : “The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential.”
*PharmaPoint: Acute Coronary Syndrome – Global Drug Forecast and Market Analysis to 2023.